Inventor · disambiguated record
Amy Han
Also filed as: HAN AMY · HAN AMY Q · HAN AMY QI
22 granted patents·32 pending applications·149 citations·filing 2000–2025
93Inventor score
Files withREGENERON PHARMA30INCYTE CORP4PROGENICS PHARM INC4BRISTOL MYERS SQUIBB PHARMA CO3ROELOFS MARK G2
Top patents by PatentIndex Score
54 records- 0197US11760775B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2020·Granted Sep 19, 2023·5 cites·9 claims
- 0296US10711032B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2017·Granted Jul 14, 2020·10 cites·33 claims
- 0395US6727366B2Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Apr 27, 2004·87 cites·4 claims
- 0494US11491237B2Cyclodextrin protein drug conjugatesREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·6 cites·59 claims
- 0589US6503901B1Amino lactam sulfonamides as inhibitors of Aβ protein productionBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted Jan 7, 2003·23 cites·42 claims
- 0687US12070506B2Steroids and antibody-conjugates thereofREGENERON PHARMA·Filed 2019·Granted Aug 27, 2024·2 cites·21 claims
- 0785US12377159B2Steroids and protein-conjugates thereofREGENERON PHARMA·Filed 2023·Granted Aug 5, 2025·0 cites·23 claims
- 0884US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
- 0981US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 1080US2025064954A1Steroids and antibody-conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1180US2024342299A1Steroids and antibody-conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1279US7576089B23-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptorsINCYTE CORP·Filed 2004·Granted Aug 18, 2009·8 cites·2 claims
- 1377US2025171622A1Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1476US8362003B23-aminopyrrolidine derivatives as modulators of chemokine receptorsINCYTE CORP·Filed 2011·Granted Jan 29, 2013·2 cites·8 claims
- 1575US12338199B2Bis-octahydrophenanthrene carboxamides and protein conjugates thereofREGENERON PHARMA·Filed 2021·Granted Jun 24, 2025·0 cites·23 claims
- 1675US2025270163A1Bis-octahydrophenanthrene carboxamides and protein conjugates thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1774US6958356B2Guanidine mimics factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Oct 25, 2005·4 cites·54 claims
- 1874US2024131175A1Optimized transglutaminase site-specific antibody conjugationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1974US2024190973A1Anti-fgfr2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2072US11866502B2Anti-FGFR2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·65 claims
- 2168US12497460B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·30 claims
- 2267US2024252661A1Protein-drug conjugates comprising camptothecin analogs and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2367US2024269308A1Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2466US12280124B2Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2021·Granted Apr 22, 2025·0 cites·33 claims
- 2566US12209180B2Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonistsREGENERON PHARMA·Filed 2019·Granted Jan 28, 2025·0 cites·45 claims
- 2666US2024182561A1Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscleREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2766US2024408223A1Hydrophilic linkers for antibody drug conjugatesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2866US2025171516A1Peptide acids as a glp1r agonist and antibody-drug conjugates thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2965US8697870B23-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptorsXUE CHU-BIAO·Filed 2008·Granted Apr 15, 2014·0 cites·2 claims
- 3064US2023330254A1Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3163US2023414775A1Tubulysins and protein-tubulysin conjugatesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3262US11786603B2Optimized transglutaminase site-specific antibody conjugationREGENERON PHARMA·Filed 2017·Granted Oct 17, 2023·0 cites·32 claims
- 3362US2023287138A1Protein-drug conjugates comprising camptothecin analogs and methods of use thereofREGNERON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3460US2014155377A13-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptorsXUE CHU-BIAO·Filed 2014·Application pending·0 cites
- 3559US2025161476A1Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3658US2017050942A13-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptorsINCYTE CORP·Filed 2016·Application pending·0 cites
- 3757US2023069722A1Tubulysins and protein-tubulysin conjugatesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3856US2018334426A1Bis-octahydrophenanthrene carboxamides and protein conjugates thereofREGENERON PHARMACEUTICAL INC·Filed 2018·Application pending·0 cites
- 3955US8729063B23-aminopyrrolidine derivatives as modulators of chemokine receptorsINCYTE CORP·Filed 2012·Granted May 20, 2014·0 cites·17 claims
- 4055US2010093878A1Crosslinkable fluoropolymer, crosslinked fluoropolymers and crosslinked fluoropolymer membranesDU PONT·Filed 2008·Application pending·0 cites
- 4154US2023348997A1Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisionsUNIV COLORADO REGENTS·Filed 2021·Application pending·0 cites
- 4253US2015231114A13-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptorsPFIZER·Filed 2015·Application pending·0 cites
- 4352US2009047279A1(R)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium AnalogsPROGENICS PHARM INC·Filed 2007·Application pending·0 cites
- 4452US2008176884A17,8-Saturated-4,5-Epoxy-Morphinanium AnalogsPROGENICS PHARM INC·Filed 2007·Application pending·0 cites
- 4551US12144864B2Tubulysins and protein-tubulysin conjugatesREGENERON PHARMA·Filed 2019·Granted Nov 19, 2024·0 cites·33 claims
- 4651US2023119539A1Traceless linkers and protein-conjugates thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4750US12134631B2Hydrophilic linkers for antibody drug conjugatesREGENERON PHARMA·Filed 2018·Granted Nov 5, 2024·0 cites·29 claims
- 4847US2003130251A1Amino lactam sulfonamides as inhibitors of A-beta protein productionFiled 2002·Application pending·0 cites
- 4946US2008161570A1Processes for Synthesizing Quaternary 4,5-Epoxy-Morphinan Analogs and Isolating their N-StereoisomersPROGENERICS PHARMACEUTICALS IN·Filed 2007·Application pending·0 cites
- 5045US2006264576A1Process to prepare stable trifluorostyrene containing compounds grafted to base polymersROELOFS MARK G·Filed 2006·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →